A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

Brief Summary

Official Title: “A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection”

This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12) in each of the treatment arms.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
  • Study Primary Completion Date: May 2015

Detailed Clinical Trial Description

Part A is being done treatment-naïve (TN), genotype 1 (GT1), interferon eligible, non-cirrhotic (N-C) participants with chronic hepatitis C (CHC). Participants will be assigned randomly to 1 of 2 treatment arms in which they will receive grazoprevir 100 mg once daily (QD) + elbasvir 20 mg or 50 mg QD and twice daily (BID) RBV, or to a treatment arm in which they will receive grazoprevir 100 mg QD + elbasvir 50 mg QD without RBV. Treatment will last 12 weeks.

In Part B, participants with hepatitis C virus (HCV) GT1 and HCV ribonucleic acid (RNA) levels of ≥10,000 IU/mL will be randomly assigned to a study arm, based on absence or presence of cirrhosis (C), whether they are TN or had poor response to previous antiviral therapy (null responders [NR]), or whether co-infected with human immunodeficiency virus (HIV); these participants will receive open-label grazoprevir (100 mg) in combination with elbasvir (50 mg) ± RBV. Treatment will last 8 to 18 weeks dependent on arm assignment.

In Part C, TN, N-C participants with HCV GT1b and HCV RNA levels of ≥10,000 IU/mL will be randomly assigned to receive open-label grazoprevir (100 mg) in combination with elbasvir (50 mg) ± RBV. Treatment will last 8 weeks.

In Part D, TN N-C participants with HCV GT3 and HCV RNA levels of ≥10,000 IU/mL will be randomly assigned to receive open-label grazoprevir (100 mg) in combination with elbasvir (50 mg) + RBV for 12 or 18 weeks.

Interventions Used in this Clinical Trial

  • Drug: Grazoprevir
    • 100 mg tablet orally QD
  • Drug: Elbasvir
    • Part A: 20 or 50 mg capsule orally QD Part B: 50 mg capsule orally QD
  • Drug: Placebo
    • Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
  • Drug: Ribavirin
    • Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: A: TN/N-C Grazoprevir+Elbasvir 20 mg+RBV
    • GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: A: TN/N-C Grazoprevir+Elbasvir 50 mg+RBV
    • GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: A: TN/N-C Grazoprevir+Elbasvir 50 mg
    • GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
  • Experimental: B: TN/N-C Grazoprevir+Elbasvir+RBV 8 wk
    • GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: B: TN/N-C Grazoprevir+Elbasvir+RBV 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: B: TN/N-C Grazoprevir+Elbasvir 12 wk
    • GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
  • Experimental: B: TN/C Grazoprevir+Elbasvir+RBV 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
  • Experimental: B: TN/C Grazoprevir+Elbasvir 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
  • Experimental: B: TN/C Grazoprevir+Elbasvir+RBV 18 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: B: TN/C Grazoprevir+Elbasvir 18 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
  • Experimental: B: NR/C/N-C Grazoprevir+Elbasvir+RBV 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: B: NR/C/N-C Grazoprevir+Elbasvir 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
  • Experimental: B: NR/C/N-C Grazoprevir+Elbasvir+RBV 18 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: B: NR/C/N-C Grazoprevir+Elbasvir 18 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
  • Experimental: B: TN/N-C/HIV Grazoprevir+Elbasvir+RBV 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: B: TN/N-C/HIV Grazoprevir+Elbasvir 12 wk
    • GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
  • Experimental: C: TN/N-C Grazoprevir+Elbasvir+RBV 8 wk
    • GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
  • Experimental: C: TN/N-C Grazoprevir+Elbasvir 8wk
    • GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
  • Experimental: D: TN/N-C Grazoprevir+Elbasvir+RBV 12 wk
    • GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
  • Experimental: D: TN/N-C Grazoprevir+Elbasvir+RBV 18 wk
    • GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight

Outcome Measures for this Clinical Trial

Primary Measures

  • Number of participants achieving Sustained Virologic Response 12 weeks after the end of all study therapy (SVR12)
    • Time Frame: Up to 30 weeks
      Safety Issue?: No
  • Number of participants experiencing at least one Adverse Event (AE) on study
    • Time Frame: Up to 42 weeks
      Safety Issue?: Yes
  • Number of participants discontinuing study therapy due to an AE
    • Time Frame: Up to 18 weeks
      Safety Issue?: Yes

Secondary Measures

  • Time to first achievement of undetectable hepatitis C virus ribonucleic acid (HCV RNA)
    • Time Frame: Up to 18 weeks
      Safety Issue?: No
  • Number of participants achieving undetectable HCV RNA at Week 2
    • Time Frame: Week 2
      Safety Issue?: No
  • Number of participants achieving undetectable HCV RNA at Week 4
    • Time Frame: Week 4
      Safety Issue?: No
  • Number of participants achieving undetectable HCV RNA at Week 12
    • Time Frame: Week 12
      Safety Issue?: No
  • Number of participants achieving HCV RNA <25 IU/mL at Week 2
    • Time Frame: Week 2
      Safety Issue?: No
  • Number of participants achieving HCV RNA <25 IU/mL at Week 4
    • Time Frame: Week 4
      Safety Issue?: No
  • Number of participants achieving HCV RNA <25 IU/mL at Week 12
    • Time Frame: Week 12
      Safety Issue?: No
  • Number of participants achieving End-Of-Treatment Response (EOTR)
    • Time Frame: Up to 18 weeks
      Safety Issue?: No
  • Number of participants achieving Sustained Virologic Response 4 weeks after the end of all therapy (SVR4)
    • Time Frame: Up to 22 weeks
      Safety Issue?: No
  • Number of participants achieving Sustained Virologic Response 24 weeks after the end of all study therapy (SVR24)
    • Time Frame: Up to 42 weeks
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

All participants – CHC genotype 1 (GT1) virus infection (Parts A, B, and C) or GT3 virus infection (Part D) – Female participants of childbearing potential or male participant with female partners of childbearing potential, must use two acceptable methods of birth control from ≥2 weeks prior to Day 1 until ≥6 months after last dose of study drug, or longer if dictated by local regulations

Part A – Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease, or cirrhosis – No evidence of advanced fibrosis, cirrhosis and/or hepatocellular carcinoma by biopsy or noninvasive testing (FibroScan and/or FibroTest)

Parts B, C, and D – Treatment naïve with or without cirrhosis, or – Prior treatment failure to Peg-IFN/Ribavirin with or without cirrhosis, or – Co-infected with human immunodeficiency virus (HIV) without cirrhosis -Absence (no medical history or physical findings) of ascites, bleeding esophageal varices, hepatic encephalopathy, or other signs or symptoms of advanced liver disease – Liver disease staging assessment by liver biopsy or noninvasive testing (FibroScan and/or FibroTest)

Exclusion Criteria

All participants – Non-GT1 HCV infection (Part A, Part B, and Part C) or a non-GT3 HCV infection (Part D) including a mixed GT infection (with a non-GT1 [Part A, Part B, and Part C] or non-GT3 [Part D]) or a non-typeable genotype – Evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC – Currently participating or participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another study – Diabetic and/or hypertensive with clinically significant ocular examination findings – History of depression associated with hospitalization for depression, electroconvulsive therapy, or resulting in prolonged absence from work and/or significant disruption of daily functions

  • Suicidal or homicidal ideations and/or attempt, or history of severe psychiatric disorders – Clinical diagnosis of substance abuse – Current history of seizure disorder, stroke, or transient ischemic attack – Immunologically mediated disease – Chronic pulmonary disease – Clinically significant cardiac abnormalities/dysfunction – Active clinical gout within the last year – Hemoglobinopathy or myelodysplastic syndromes History of organ transplants including hematopoietic stem cell transplants – Poor venous access – Indwelling venous catheter – History of gastric surgery or malabsorption disorders – Severe concurrent disease – Evidence of active or suspected malignancy, or a history of malignancy, ≤5 years before – Pregnant, lactating, expecting to conceive or donate eggs – Male participant with pregnant female partner – Member/family member of the investigational study or sponsor staff directly involved with this study – Evidence or history of chronic hepatitis not caused by HCV
  • Part A – Not treatment-naïve – Documented to be HIV positive – Taking or planning to take significant inducers or inhibitors of CYP3A4 substrates or herbal supplements 2 weeks prior to start of study medications

    Parts B, C, and D – Previously received any HCV direct-acting antivirals – Requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial – For participants diagnosed with diabetes mellitus, documented HbA1c >8.5%

    Gender Eligibility for this Clinical Trial: Both

    Minimum Age for this Clinical Trial: 18 Years

    Maximum Age for this Clinical Trial: N/A

    Are Healthy Volunteers Accepted for this Clinical Trial: No

    Clinical Trial Investigator Information

    • Lead Sponsor
      • Merck Sharp & Dohme Corp.
    • Provider of Information About this Clinical Study
      • Sponsor

    Source

    Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

    The URL of this page is:
    http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01717326